ArticleFrontiers of medicine2021
Astragaloside IV suppresses post-ischemic natural killer cell infiltration and activation in the brain: involvement of histone deacetylase inhibition.
Article in Frontiers of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Astragaloside II suppresses colorectal cancer progression by upregulating LGALS4 expression.Journal of molecular histology · 2026Article
- Astragaloside IV suppresses neuroinflammation via PI3K/Akt/NF-κB to ameliorate cerebral ischemia-reperfusion injury based on network pharmacology analysis and experimental validation.Frontiers in immunology · 2026Article
- Beyond Traditional Use: The Scientific Evidence for the Role ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Chemical Composition and Therapeutic Effects of Several Astragalus Species (Fabaceae).Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2024Review
- Phytogenic feed additives as natural antibiotic alternatives in animal health and production: A review of the literature of the last decade.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Review
- Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging.Aging and disease · 2022Review
- Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2022Article
- The Role of CCL2/CCR2 Axis in Cerebral Ischemia-Reperfusion Injury and Treatment: From Animal Experiments to Clinical Trials.International journal of molecular sciences · 2022Review
- The protective effect of Buzhong Yiqi decoction on ischemic stroke mice and the mechanism of gut microbiota.Frontiers in neuroscience · 2022Article
- A Review of Traditional Chinese Medicine, Buyang Huanwu Decoction for the Treatment of Cerebral Small Vessel Disease.Frontiers in neuroscience · 2022Review
- Construction of a ceRNA immunoregulatory network related to the development of vascular dementia through a weighted gene coexpression network analysis.Annals of translational medicine · 2021Article
- Suppressing NK Cells by Astragaloside IV Protects Against Acute Ischemic Stroke in MiceFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells, a type of cytotoxic lymphocytes, can infiltrate into ischemic brain and exacerbate neuronal cell death. Astragaloside IV (ASIV) is the major bioactive ingredient of Astragalus membranaceus, a Chinese herbal medicine, and possesses potent immunomodulatory and neuroprotective properties. This study investigated the effects of ASIV on post-ischemic brain infiltration and activation of NK cells. ASIV reduced brain infarction and alleviated functional deficits in MCAO rats, and these beneficial effects persisted for at least 7 days. Abundant NK cells infiltrated into the ischemic hemisphere on day 1 after brain ischemia, and this infiltration was suppressed by ASIV. Strikingly, ASIV reversed NK cell deficiency in the spleen and blood after brain ischemia. ASIV inhibited astrocyte-derived CCL2 upregulation and reduced CCR2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.